Anemia is the most common complication of pregnancy, which has significant negative consequences for both mother and fetus. According to the WHO data, the incidence of iron-deficiency anemia (IDA) in pregnant women amounts to as much as 80—90%; according to the data of the Ministry of Health of the Russian Federation, that has increased by more than 6 times in the past 10 years. Iron, like any trace element, performs its biological functions, interacting with many other micronutrients involved in human metabolism. This investigation has dealt with a bioinformatics analysis of all iron molecular synergists that, along with Fe2+ ions and hemes, are protein cofactors in the human proteome. Iron cannot perform biological functions without iron synergid protein cofactors, such as heme, Cu2+, Zn2+, Ca2+, and Mn2+ ions, flavin and nicotinamide cofactors, ascorbic acid, retinoids, pyridoxine, quinone, cobalamin, etc. The results of the investigation point to the fundamental value of the concurrent use of iron with its molecular synergists for the prevention and treatment of iron deficiency-related diseases in pregnant women. At the present time, the WHO recommends that pregnant women should take ferrous fumarate-based preparations (Vitrum Prenatal Forte), for the latter are well assimilated by the organism, do not exert prooxidant activity or cause adverse reactions. The authors declare no conflicts of interest.